Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients
Cancers · 23.08.2024 · 16 (17) · 2929
DOI: 10.3390/cancers16172929 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 23.08.2024. Verfasst von Ilaria Vigliotta und 19 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", 40138 Bologna, Italy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
In recent years, liquid biopsy has emerged as a promising alternative to the bone marrow (BM) examination, since it is a minimally invasive technique allowing serial monitoring. Circulating multiple myeloma cells (CMMCs) enumerated using CELLSEARCH® were correlated with patients’ prognosis and measured under treatment to assess their role in monitoring disease dynamics. Forty-four MM and seven smouldering MM (SMM) patients were studied. The CMMC medians at diagnosis were 349 (1 to 39,940) and 327 (range 22–2463) for MM and SMM, respectively. In the MM patients, the CMMC count was correlated with serum albumin, calcium, β2-microglobulin, and monoclonal components (p < 0.04). Under therapy, the CMMCs were consistently detectable in 15/40 patients (coMMstant = 1) and were undetectable or decreasing in 25/40 patients (coMMstant = 0). High-quality response rates were lower in the coMMstant = 1 group (p = 0.04), with a 7.8-fold higher risk of death (p = 0.039), suggesting that continuous CMMC release is correlated with poor responses. In four MM patients, a single-cell DNA sequencing analysis on residual CMMCs confirmed the genomic pattern of the aberrations observed in the BM samples, also highlighting the presence of emerging clones. The CMMC kinetics during treatment were used to separate the patients into two subgroups based on the coMMstant index, with different responses and survival probabilities, providing evidence that CMMC persistence is associated with a poor disease course.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", 40138 Bologna, Italy.
- Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.
- Menarini Silicon Biosystems SpA, Via Giuseppe di Vittorio, Castel Maggiore, 40013 Bologna, Italy.
ORCID-Profile: Ilaria Vigliotta, Vincenza Solli, Silvia Armuzzi, Marina Martello, Andrea Poletti, Gaia Mazzocchetti, Enrica Borsi, Elena Zamagni, Alberto Ferrarini, Nicolò Manaresi, Michele Cavo
Förderung
- Italian Ministry of Health
Zitieren
APA
Vigliotta, I., Solli, V., Armuzzi, S., Martello, M., Poletti, A., Taurisano, B., Pistis, I., Mazzocchetti, G., Borsi, E., Pantani, L., Marzocchi, G., Testoni, N., Zamagni, E., Terracciano, M., Tononi, P., Garonzi, M., Ferrarini, A., Manaresi, N., Cavo, M., & Terragna, C. (2024). Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients. Cancers, 16(17), 2929. https://doi.org/10.3390/cancers16172929
Vancouver
Vigliotta I, Solli V, Armuzzi S, Martello M, Poletti A, Taurisano B, et al. Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients. Cancers. 2024;16(17):2929. doi:10.3390/cancers16172929
BibTeX
@article{Vigliotta2024,
author = {Vigliotta, Ilaria and Solli, Vincenza and Armuzzi, Silvia and Martello, Marina and Poletti, Andrea and Taurisano, Barbara and Pistis, Ignazia and Mazzocchetti, Gaia and Borsi, Enrica and Pantani, Lucia and Marzocchi, Giulia and Testoni, Nicoletta and Zamagni, Elena and Terracciano, Mario and Tononi, Paola and Garonzi, Marianna and Ferrarini, Alberto and Manaresi, Nicolò and Cavo, Michele and Terragna, Carolina},
title = {Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients},
journal = {Cancers},
year = {2024},
volume = {16},
number = {17},
pages = {2929},
doi = {10.3390/cancers16172929}
}
EUVIMED